Efficacy of rabeprazole-based therapy in laryngopharyngeal reflux disease: a prospective comparative study

Parag Bhayal; Sudhakar Vaidya; Sumeer Verma

doi:10.18203/issn.2454-5929.ijohns20261496

Authors

Parag Bhayal Department of Otorhinolaryngology, R.D. Gardi Medical College, Ujjain, Madhya Pradesh, India
Sudhakar Vaidya Department of Otorhinolaryngology, R.D. Gardi Medical College, Ujjain, Madhya Pradesh, India
Sumeer Verma Department of Otorhinolaryngology, R.D. Gardi Medical College, Ujjain, Madhya Pradesh, India

DOI:

https://doi.org/10.18203/issn.2454-5929.ijohns20261496

Keywords:

Laryngopharyngeal reflux, Proton pump inhibitor, Rabeprazole, Reflux symptom index, Reflux finding score

Abstract

Background: Laryngopharyngeal reflux disease (LPRD) is a common condition presenting to otolaryngology clinics, yet the role of proton pump inhibitors in treatment remains controversial. This study aimed to evaluate the efficacy of proton pump inhibitor therapy combined with alginate and lifestyle modifications in managing LPRD.

Methods: A prospective, comparative interventional study was conducted at a tertiary care hospital from August 2023 to April 2025. One hundred twenty patients aged 18-80 years with clinically diagnosed LPRD (Reflux Symptom Index ≥13, Reflux Finding Score ≥7) were randomly assigned to case and control groups (n=60 each). The case group received rabeprazole 20 mg twice daily, domperidone 10 mg twice daily, alginate 10 ml three times daily, and lifestyle modifications. The control group received identical treatment except rabeprazole. Primary outcomes were changes in RSI and RFS after 6 weeks of treatment. Statistical significance was evaluated with p-values.

Results: Both groups showed significant baseline comparability. After 6 weeks, the case group demonstrated superior improvement compared to controls. Mean RSI decreased from 20.6±3.5 to 10.5±3.2 in the case group versus 20.8±3.7 to 12.8±2.5 in controls (p<0.001). Mean RFS improved from 11.5±3.6 to 5.8±2.5 in cases versus 11.8±3.5 to 7.7±2.4 in controls (p<0.001). Individual symptoms, including hoarseness (p=0.04) and throat clearing (p=0.012), showed statistically significant improvements favoring the case group.

Conclusions: Proton pump inhibitor therapy with rabeprazole, combined with lifestyle modifications and adjunctive medications, provides superior symptomatic and objective improvement in LPRD compared to lifestyle modifications alone, supporting inclusion of PPIs in first-line LPRD management protocols.

References

Koufman JA. The otolaryngologic manifestations of gastroesophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury. Laryngoscope. 1991;101(53):1-78.

Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005;54(5):710-7.

Johnston N, Knight J, Dettmar PW, Lively MO, Koufman J. Pepsin and carbonic anhydrase isoenzyme III as diagnostic markers for laryngopharyngeal reflux disease. Laryngoscope. 2004;114(12):2129-34.

Belafsky PC, Postma GN, Koufman JA. Validity and reliability of the reflux symptom index (RSI). J Voice. 2002;16(2):274-7.

Qadeer MA, Phillips CO, Lopez AR, Steward DL, Noordzij JP, Wo JM, et al. Proton pump inhibitor therapy for suspected GERD-related chronic laryngitis: a meta-analysis of randomized controlled trials. Am J Gastroenterol. 2006;101(11):2646-54.

Park W, Hicks DM, Khandwala F, Richter JE, Abelson TI, Milstein C, et al. Laryngopharyngeal reflux: prospective cohort study evaluating optimal dose of proton-pump inhibitor therapy and pretherapy predictors of response. Laryngoscope. 2005;115(7):1230-8.

Belafsky PC, Postma GN, Koufman JA. The validity and reliability of the reflux finding score (RFS). Laryngoscope. 2001;111(8):1313-7.

Francis DO, Rymer JA, Slaughter JC, Choksi Y, Jiramongkolchai P, Ogbeide E, et al. High economic burden of caring for patients with suspected extraesophageal reflux. Am J Gastroenterol. 2013;108(6):905-11.

Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112(6):1798-810.

Mandel KG, Daggy BP, Brodie DA, Jacoby HI. Review article: alginate-raft formulations in the treatment of heartburn and acid reflux. Aliment Pharmacol Ther. 2000;14(6):669-90.

Vaezi MF, Hicks DM, Abelson TI, Richter JE. Laryngeal signs and symptoms and gastroesophageal reflux disease (GERD): a critical assessment of cause-and-effect association. Clin Gastroenterol Hepatol. 2003;1(5):333-44.

Koufman JA, Aviv JE, Casiano RR, Shaw GY. Laryngopharyngeal reflux: position statement of the committee on speech, voice, and swallowing disorders of the American Academy of Otolaryngology-Head and Neck Surgery. Otolaryngol Head Neck Surg. 2002;127(1):32-5.

Reichel O, Dressel H, Wiederänders K, Issing WJ. Double-blind, placebo-controlled trial with esomeprazole for symptoms and signs associated with laryngopharyngeal reflux. Otolaryngol Head Neck Surg. 2008;139(3):414-20.

Swoger J, Ponsky J, Hicks DM, Richter JE, Abelson TI, Milstein C, et al. Surgical fundoplication in laryngopharyngeal reflux unresponsive to aggressive acid suppression: a controlled study. Clin Gastroenterol Hepatol. 2006;4(4):433-41.

DelGaudio JM, Woosley JT. Relationship of laryngeal pseudosulcus to reflux disease. Laryngoscope. 2007;117(9):1570-5.

Ford CN. Evaluation and management of laryngopharyngeal reflux. JAMA. 2005;294(12):1534-40.

Gill GA, Johnston N, Buda A, Pignatelli M, Pearson J, Dettmar PW, et al. Laryngeal epithelial defenses against laryngopharyngeal reflux: investigations of E-cadherin, carbonic anhydrase isoenzyme III, and pepsin. Ann Otol Rhinol Laryngol. 2005;114(12):913-21.

Book DT, Rhee JS, Toohill RJ, Smith TL. Perspectives in laryngopharyngeal reflux: an international survey. Laryngoscope. 2002;112(1):1399-406.